The present invention discloses polymorphic free bases or polymorphic acid salts of C-Met inhibitor, preparation method and the use thereof. In particular, the present invention discloses polymorphic form free bases or polymorphic form acid salts of C-Met / HGFR (hepatocyte growth factor receptor) kinase inhibitors, 9 - ((8-fluoro-6-(1-methyl-pyrazol-4 -1H- yl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) thio) -4-methyl--2H- [1,4] oxa-linked Nitrogen [3, 2-c] quinoline -3 (4H) - ketone, preparation method and the application thereof. The said polymorphic free bases are selected from free base polymorph I of which powder X-ray diffraction pattern includes the diffraction peaks(2 θ) of 13.0 ± 0.2°, 17.9 ± 0.2°, 21.2 ± 0.2° and 31.4 ± 0.2°, free base polymorph II of which powder X-ray diffraction pattern includes the diffraction peaks(2 θ) of 8.6±0.2°, 11.5±0.2°, 14.1±0.2° and 19.8±0.2°, free base polymorph III of which powder X-ray diffraction pattern includes the diffraction peaks(2 θ) of 12.8±0.2°, 14.8±0.2°, 18.0±0.2° and 20.5±0.2°, or free base polymorph IV of which powder X-ray diffraction pattern includes the diffraction peaks(2 θ) of 8.9±0.2°, 12.6±0.2°, 17.0±0.2° and 17.9±0.2°. They can be used in the preparation of drugs related to protein kinases, protein kinase inhibitors and antitumor drugs, the products of this invention have wide range application.本發明公開了C-Met抑制劑結晶型游離鹼或其結晶型酸式鹽及其製備方法和應用。具體地，本發明公開了一種C-Met/HGFR(肝細胞生長因子受體)激酶抑制劑結晶型9-((8-氟-6-(1-甲基-1H-吡唑-4-基)-[1,2,4]三唑並[4,3-a]吡啶-3-基)硫基)-4-甲基-2H-[1,4]氧雜聯氮基[3,2-c]喹啉-3(4H)-酮游離鹼或其結晶型酸式鹽及其製備方法和應用，其中該結晶型游離鹼選自：游離鹼晶型I，其粉末X射線衍射圖包括位於13.0±0.2°，17.9±0.2°，21.2±0.2°和31.4±0.2°的衍射角(2 θ)處的峰；游離鹼晶型II，其粉末X射線衍射圖包括位於8.6±0.2°，11.5±0.2°，14.1±0.2°和19.8±0.2°的衍射角(2 θ)處的峰；游離鹼晶型III，其粉末X射線衍射圖包括位於12.8±0.2°，14.8±0.2°，18.0±0.2°和20.5±0.2°的衍射角(2 θ)處的峰；或游離鹼晶型IV，其粉末X射線衍射圖包括位於8.9±0.2°，12.6±0.2°，17.0±0.2°和17.9±0.2°的衍射角(2 θ)處的峰。其可應用於製備治療與蛋白質激有關的疾病藥物、蛋白激酶抑制劑、抗腫瘤藥物等，具有廣泛的應用前景。
